IVX · ASX

Invion Ltd. (ASX:IVX)

AU$0.1

 0.0 (0.0%)
ASX:Live
12/03/2025 02:47:35 PM
Volume Spike Near 52 Week Low HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

IVX Overview

IVX Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About IVX

Website

Invion Ltd.

Telephone

61.3.9692.7222

Address

692 High Street East Kew, Victoria (VIC) 3102

Description

Invion Ltd. is a clinical-stage life sciences company, which engages in the research and development of treatment for cancers, atherosclerosis, and infectious diseases. The company was founded on October 11, 2000 and is headquartered in Melbourne, Australia.

IVX Price Chart

Key Stats

Market Cap

AU$8.09M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.1 - 0.6

Trade Value (12mth)

AU$3,193.00

1 week

-19.23%

1 month

-27.59%

YTD

-61.47%

1 year

-79%

All time high

55.25

Key Fundamentals

EPS 3 yr Growth

225.90%

EBITDA Margin

-131.60%

Operating Cashflow

-$2m

Free Cash Flow Return

-14.60%

ROIC

-34.30%

Interest Coverage

N/A

Quick Ratio

2.10

Other Data

Shares on Issue (Fully Dilluted)

67m

HALO Sector

Healthcare

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

IVX Announcements

Latest Announcements

Date Announcements

11 March 25

Update - Proposed issue of securities - IVX

×

Update - Proposed issue of securities - IVX

05 March 25

Share Purchase Agreement Termination and Tranche Repayment

×

Share Purchase Agreement Termination and Tranche Repayment

05 March 25

Cancel - Application for quotation of securities - IVX

×

Cancel - Application for quotation of securities - IVX

04 March 25

Completion Of Placement to Accelerate Clinical Programs

×

Completion Of Placement to Accelerate Clinical Programs

04 March 25

Proposed issue of securities - IVX

×

Proposed issue of securities - IVX

04 March 25

Application for quotation of securities - IVX

×

Application for quotation of securities - IVX

04 March 25

Section 708A Cleansing Statement

×

Section 708A Cleansing Statement

28 February 25

Trading Halt

×

Trading Halt

28 February 25

Appendix 4D and Half Year Financial Report

×

Appendix 4D and Half Year Financial Report

26 February 25

Oesophageal Cancer Collaboration and Funding Agreement

×

Oesophageal Cancer Collaboration and Funding Agreement

31 January 25

Activities Report and Appendix 4C

×

Activities Report and Appendix 4C

23 January 25

Application for quotation of securities - IVX

×

Application for quotation of securities - IVX

23 January 25

Section 708A Cleansing Statement

×

Section 708A Cleansing Statement

14 January 25

Notification regarding unquoted securities - IVX

×

Notification regarding unquoted securities - IVX

02 January 25

Application for quotation of securities - IVX

×

Application for quotation of securities - IVX

02 January 25

Section 708A Cleansing Statement

×

Section 708A Cleansing Statement

16 December 24

Prof Rob Ramsay from Peter Mac Appointed Scientific Advisor

×

Prof Rob Ramsay from Peter Mac Appointed Scientific Advisor

16 December 24

Application for quotation of securities - IVX

×

Application for quotation of securities - IVX

16 December 24

Section 708A Cleansing Statement

×

Section 708A Cleansing Statement

11 December 24

Notification regarding unquoted securities - IVX

×

Notification regarding unquoted securities - IVX

11 December 24

Change of Director's Interest Notice- Thian Chew

×

Change of Director's Interest Notice- Thian Chew

11 December 24

Change of Director's Interest Notice - Alan Yamashita

×

Change of Director's Interest Notice - Alan Yamashita

11 December 24

Change of Director's Interest Notice - Alistair Bennallack

×

Change of Director's Interest Notice - Alistair Bennallack

03 December 24

Invion Doses First Patient in Phase I/II Skin Cancer Trial

×

Invion Doses First Patient in Phase I/II Skin Cancer Trial

28 November 24

Completion of Securities Consolidation

×

Completion of Securities Consolidation

IVX Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.04 -0.02 -0.09 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.04 -0.02 -0.09 Lock Lock Lock
     Growth % Lock Lock Lock Lock -37.0 32.4 -252.0 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.01 -0.01 -0.00 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.02 -0.03 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -71.8 17.6 46.9 Lock Lock Lock
     Yield % Lock Lock Lock Lock -2.0 -7.4 -9.3 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.31 0.29 0.22 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.13 0.08 0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock 3,031.7 -36.9 -79.2 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 61 64 64 Lock Lock Lock
Basic m Lock Lock Lock Lock 61 64 64 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 3 4 4 Lock Lock Lock
     Growth % Lock Lock Lock Lock 41.3 24.7 -10.0 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 5 5 9 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -2 -1 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -46.7 49.2 -403.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock -57.7 -23.5 -131.6 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 0 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -2 -2 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -47.6 29.0 -244.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock -70.5 -40.2 -153.7 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -2 -2 -6 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -2 -2 -6 Lock Lock Lock
     Growth % Lock Lock Lock Lock -51.1 28.0 -248.5 Lock Lock Lock
     Margin % Lock Lock Lock Lock -68.1 -39.3 -152.3 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -1 -2 -2 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 7 3 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -7 -3 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 16 0 0 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -1 -2 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock -365.3 -70.3 -27.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -0.3 -0.5 -0.7 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 8 4 1 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 20 19 15 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -8 -4 -1 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 0 1 1 Lock Lock Lock
Equity $m Lock Lock Lock Lock 20 18 14 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 20 18 14 Lock Lock Lock
     Growth % Lock Lock Lock Lock 308.7 -6.0 -21.5 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -11.2 -8.5 -36.4 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -11.4 -8.8 -39.0 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -19.1 -8.7 -34.6 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -18.4 -8.5 -34.3 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -9.1 -9.5 -14.6 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 4.5 4.2 0.2 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -43.3 -22.2 -5.4 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 18.7 8.9 2.1 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 18.7 8.9 2.1 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 98.0 70.9 37.6 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -239.8 -278.6 -236.9 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 43.6 4.7 2.6 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.4 0.8 3.5 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 6.7 9.7 19.5 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.2 0.2 0.2 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.2 0.2 0.2 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -68.1 -39.3 -152.3 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -11.2 -8.5 -36.4 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -11.2 -8.5 -36.4 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.0 1.0 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -11.4 -8.8 -39.0 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -11.4 -8.8 -39.0 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 8.4 78.1 139.6 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 8.4 78.1 139.6 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 8.4 78.1 139.6 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

IVX Shortsell

Frequently Asked Questions

The current share price of Invion Ltd. (IVX:ASX) is AU$0.1.
The 52-week high share price for Invion Ltd. (IVX:ASX) is AU$0.60.
The 52-week low share price for Invion Ltd. (IVX:ASX)? is AU$0.10.
Invion Ltd. (IVX:ASX) does not pay a dividend.
Invion Ltd. (IVX:ASX) does not pay a dividend.
Invion Ltd. (IVX:ASX) has a franking level of 0.0%.
Invion Ltd. (IVX:ASX) is classified in the Healthcare.
The current P/E ratio for Invion Ltd. (IVX:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.